A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease

Kelly L. Sullivan

A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease

Kelly L. Sullivan

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Epidemiology
Public Health

Cite this

@misc{9d9faebfdf1c4ad0992f1f666a210f12,

title = "A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease",

author = "Sullivan, \{Kelly L.\}",

note = "Kelly L. Sullivan (Coordinator), {"}A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease,{"} GlaxoSmithKline. (2012-present).",

year = "2012",

language = "American English",

type = "Other",

}

TY - GEN

T1 - A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Coordinator), "A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease," GlaxoSmithKline. (2012-present).

PY - 2012

Y1 - 2012

UR - https://clinicaltrials.gov/ct2/show/NCT01494532

M3 - Other

ER -

A Fixed Dose Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment in Patients with Advanced Parkinson's Disease

UN SDGs

Disciplines

Other files and links

Cite this